Display options
Cite
Siadat SD, Vaziri F, Eftekhary M, et al. Preparation and Evaluation of a New Lipopolysaccharide-based Conjugate as a Vaccine Candidate for Brucellosis. Osong Public Health Res Perspect. 2014;6(1):9-13doi: 10.1016/j.phrp.2014.10.012.
Siadat, S. D., Vaziri, F., Eftekhary, M., Karbasian, M., Moshiri, A., Aghasadeghi, M. R., Ardestani, M. S., Alitappeh, M. A., Arsang, A., Fateh, A., Peerayeh, S. N., & Bahrmand, A. R. (2015). Preparation and Evaluation of a New Lipopolysaccharide-based Conjugate as a Vaccine Candidate for Brucellosis. Osong public health and research perspectives, 6(1), 9-13. https://doi.org/10.1016/j.phrp.2014.10.012
Siadat, Seyed Davar, et al. "Preparation and Evaluation of a New Lipopolysaccharide-based Conjugate as a Vaccine Candidate for Brucellosis." Osong public health and research perspectives vol. 6,1 (2015): 9-13. doi: https://doi.org/10.1016/j.phrp.2014.10.012
Siadat SD, Vaziri F, Eftekhary M, Karbasian M, Moshiri A, Aghasadeghi MR, Ardestani MS, Alitappeh MA, Arsang A, Fateh A, Peerayeh SN, Bahrmand AR. Preparation and Evaluation of a New Lipopolysaccharide-based Conjugate as a Vaccine Candidate for Brucellosis. Osong Public Health Res Perspect. 2015 Feb;6(1):9-13. doi: 10.1016/j.phrp.2014.10.012. Epub 2014 Dec 18. PMID: 25737825; PMCID: PMC4346588.
Copy Download .nbib Format: NLM
Share it on

Osong Public Health Res Perspect. 2015 Feb;6(1):9-13. doi: 10.1016/j.phrp.2014.10.012. Epub 2014 Dec 18.

Preparation and Evaluation of a New Lipopolysaccharide-based Conjugate as a Vaccine Candidate for Brucellosis.

Osong public health and research perspectives

Seyed Davar Siadat, Farzam Vaziri, Mamak Eftekhary, Maryam Karbasian, Arfa Moshiri, Mohammad R Aghasadeghi, Mehdi S Ardestani, Meghdad Abdollahpour Alitappeh, Amin Arsang, Abolfazl Fateh, Shahin Najar Peerayeh, Ahmad R Bahrmand

Affiliations

  1. Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran ; Department of Microbiology, Pasteur Institute of Iran, Tehran, Iran.
  2. Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
  3. Department of Microbiology, Iran University of Medical Sciences, Tehran, Iran.
  4. Department of Microbiology, Pasteur Institute of Iran, Tehran, Iran.
  5. Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  6. Department of Hepatitis & AIDS, Pasteur Institute of Iran, Tehran, Iran.
  7. Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

PMID: 25737825 PMCID: PMC4346588 DOI: 10.1016/j.phrp.2014.10.012

Abstract

OBJECTIVES: Development of an efficacious vaccine against brucellosis has been a challenge for scientists for many years. At present, there is no licensed vaccine against human brucellosis. To overcome this problem, currently, antigenic determinants of Brucella cell wall such as Lipopolysaccharide (LPS) are considered as potential candidates to develop subunit vaccines.

METHODS: In this study, Brucella abortus LPS was used for conjugation to Neisseria meningitidis serogroup B outer membrane vesicle (OMV) as carrier protein using carbodiimide and adipic acid-mediated coupling and linking, respectively. Groups of eight BALB/c mice were injected subcutaneously with 10 μg LPS alone, combined LPS + OMV and conjugated LPS-OMV on 0 days, 14 days, 28 days and 42 days. Anti-LPS IgG was measured in serum.

RESULTS: The yield of LPS to OMV in LPS-OMV conjugate was 46.55%, on the basis of carbohydrate content. The ratio for LPS to OMV was 4.07. The LPS-OMV conjugate was the most immunogenic compound that stimulated following the first injection with increased IgG titer of ∼5-fold and ∼1.3-fold higher than that produced against LPS and LPS in noncovalent complex to OMV (LPS + OMV), respectively. The highest anti-LPS IgG titer was detected 2 weeks after the third injection (Day 42) of LPS-OMV conjugate. The conjugated compound elicited higher titers of IgG than LPS + OMV, that showed a 100-120-fold rise of anti-LPS IgG in mice.

CONCLUSION: These results indicate that our conjugated LPS-OMV can be used as a brucellosis vaccine, but further investigation is required.

Keywords: brucellosis; conjugate vaccine; lipopolysaccharide; outer membrane vesicle; vaccine candidate

References

  1. Vaccine. 2006 Apr 12;24 Suppl 2:S2-74-5 - PubMed
  2. Vaccine. 2006 Jan 12;24(2):206-14 - PubMed
  3. Vaccine. 1991 Dec;9(12):896-900 - PubMed
  4. Infect Immun. 2007 Jun;75(6):2974-80 - PubMed
  5. Vaccine. 1996 Jul;14(10):959-62 - PubMed
  6. Vaccine. 2006 Apr 12;24 Suppl 2:S2-76-8 - PubMed
  7. Infect Immun. 1988 Nov;56(11):2808-17 - PubMed
  8. Clin Microbiol Infect. 2003 Feb;9(2):79-85 - PubMed
  9. Infect Immun. 2006 Oct;74(10):5820-5 - PubMed
  10. Pak J Biol Sci. 2007 Oct 15;10(20):3578-84 - PubMed
  11. Infect Immun. 2003 Sep;71(9):5115-20 - PubMed
  12. Infect Immun. 2005 May;73(5):2790-6 - PubMed
  13. J Gen Microbiol. 1993 Jul;139(7):1551-6 - PubMed

Publication Types